Pulmatrix Announces Positive Results From Initial Stage of Phase IB Clinical Study of PUR0200 in COPD Patients

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LEXINGTON, Mass.--(BUSINESS WIRE)--Pulmatrix today announced the successful completion and positive results of the first part of a two-part Phase IB clinical study in chronic obstructive pulmonary disease (COPD) patients with their lead clinical candidate PUR0200. PUR0200 is a bronchodilator therapy for COPD and is the first small molecule product from the company's novel iSPERSEā„¢ inhaled dry powder technology. The first part of the Phase 1B clinical trial evaluated the safety, tolerability and the pharmacokinetic/pharmacodynamic profile of single ascending doses of PUR0200 in patients with moderate COPD.

Help employers find you! Check out all the jobs and post your resume.

Back to news